<DOC>
	<DOCNO>NCT01097005</DOCNO>
	<brief_summary>To evaluate efficacy safety long-term treatment clarithromycin patient Non-tuberculous Mycobacterial Pulmonary Infections .</brief_summary>
	<brief_title>Special Investigation Clarith/Klaricid Patients With Non-tuberculous Mycobacterial Pulmonary Infections</brief_title>
	<detailed_description>Background : The revised 2007 American Thoracic Society/Infectious Diseases Society America guideline recommend clarithromycin-based combination therapy treatment Mycobacterium avium complex ( MAC ) lung disease stipulate approximately 1 year continuous treatment bacillus negative conversion . However , support data insufficient . Objectives : To obtain data clinical outcome clarithromycin-based regimen conduct nationwide prospective study mainly MAC lung disease . Methods : In accordance guideline , patient enrol survey accord chest radiographic finding microbiologic test result . They treat multi-drug regimen include clarithromycin , rifampicin , ethambutol ( clarithromycin -based regimen ) bacilli negative conversion continual treatment 1 year . Data collect `` pre-administration , '' `` bacillus negative conversion , '' `` 6 month end treatment . ''</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium Infections , Nontuberculous</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Inclusion Criteria Patients Pulmonary nontuberculous mycoplasma infection indicate treatment Klaricid Exclusion Criteria Contraindications accord package insert Patients history hypersensitivity ingredient Klaricid Patients receive pimozide , ergotcontaining product , cisapride Patients AIDS ( Acquired Immune Deficiency Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Mycobacterium Infections , Atypical</keyword>
</DOC>